JPMorgan Starts Rigel Pharmaceuticals (RIGL) at Overweight
RIGL Hot Sheet
Rating Summary:4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
JPMorgan initiates coverage on Rigel Pharmaceuticals (NASDAQ: RIGL) with an Overweight. PT $14.00.
For more ratings news on Rigel Pharmaceuticals click here and for the rating history of Rigel Pharmaceuticals click here.
Shares of Rigel Pharmaceuticals closed at $6.97 yesterday, with a 52 week range of $6.42-$10.21.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
For more ratings news on Rigel Pharmaceuticals click here and for the rating history of Rigel Pharmaceuticals click here.
Shares of Rigel Pharmaceuticals closed at $6.97 yesterday, with a 52 week range of $6.42-$10.21.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- Oppenheimer Starts Ellie Mae (ELLI) at Outperform
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
Create E-mail Alert Related Categories
New CoverageRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
